Most chronic fatigue, metabolic inflexibility, and slow recovery eventually show up as an energy-production problem. The cause may be under-fueling, thyroid drag, inflammation, poor sleep, post-viral stress, GLP-1 titration, or overtraining — but the bottleneck often lands in the mitochondria, where cells have to turn fuel into usable ATP.
The Mito Stack addresses that bottleneck from three angles: SS-31 protects the physical membrane where energy is made, MOTS-c sends the adaptation signal that builds more capacity, and NAD+ supplies the redox currency both processes spend.
The practical case is strongest for two populations:
- Those experiencing GLP-1 fatigue (where rapid caloric deficit from semaglutide, tirzepatide, or retatrutide strains mitochondrial capacity)
- Individuals with chronic energy depletion from illness, overtraining, or age-related decline.
The protocol runs in 12-week cycles — SS-31 loads first to repair membrane integrity (with NAD+ layered in as support), then MOTS-c is added in to build capacity on a repaired foundation.
At a Glance
| Component | Core role |
|---|---|
| SS-31 | Repairs mitochondrial membranes, reducing electron leak and oxidative damage |
| MOTS-c | Retrains metabolic signaling — improves fuel flexibility and builds new mitochondria |
| NAD+ | Restores the redox currency cells need for energy production, DNA repair, and longevity enzymes |
| Protocol cadence | 12-week cycles with loading and maintenance phases |
| Complementary | L-Carnitine injectable for fatty acid transport; 5-Amino-1MQ as optional adipose-side support |
| Primary applications | Fatigue, metabolic dysfunction, injury recovery support, and longevity support |
What Is a Mitochondrial Peptide Stack?
This stack combines three compounds that target different aspects of mitochondrial function — structure (SS-31), signaling (MOTS-c), and redox support (NAD+). These are the three layers that determine whether mitochondria can keep up with the work being asked of them.
MOTS-c is part of the body's exercise-response system — a peptide mitochondria release during physical stress to reprogram how cells use energy. SS-31 protects the membrane where energy production actually happens, the part that degrades with age, inflammation, and oxidative stress. NAD+ is the redox currency both processes run on, and it declines measurably with age and chronic load.
Each addresses a different failure point. MOTS-c tells cells to build better mitochondria. SS-31 keeps existing ones from breaking down. NAD+ makes sure there's enough energy currency to power both.
The Three Axes of Mitochondrial Health
| Axis | Function | How It Fails | Result |
|---|---|---|---|
| Cardiolipin integrity | Anchors electron transport chain | Oxidized membranes leak electrons | Low ATP, high ROS, inflammation |
| Redox currency (NAD+) | Powers enzymes, activates sirtuins | Depleted by stress, aging, alcohol | Fatigue, DNA damage, metabolic rigidity |
| Adaptive signaling (AMPK → PGC-1α) | Drives mitochondrial biogenesis | Blunted by cortisol, nutrient overload | Slow recovery, weight gain |
Component 1: SS-31 — Membrane Repair
Every mitochondrion has an inner membrane where energy production happens. That membrane depends on a specific molecule — cardiolipin — to hold the energy-producing machinery in place. As cardiolipin degrades from age and oxidative stress, the machinery loosens. Energy output drops. Waste products (reactive oxygen species) spike. The mitochondrion starts costing more to run than it produces.
SS-31 (also called Elamipretide) stabilizes cardiolipin directly — tightening the energy-producing chain so it runs cleanly instead of leaking. The best fit is a system where that membrane is already stressed: aging, post-viral fatigue, overtraining, metabolic stress, or a known mitochondrial condition. When mitochondria are already young and healthy, there may be less damaged membrane for SS-31 to protect.
SS-31 has the most advanced clinical data of any mitochondrial peptide¹. Its approved use is narrow — Barth syndrome — but that approval matters because it confirms the cardiolipin-protection mechanism in humans, not just in cell models.
See SS-31 guide for complete coverage.
Component 2: MOTS-c — Metabolic Reprogramming
Your body already makes MOTS-c — mitochondria release it during exercise. It's the signal that tells cells to adapt: build more mitochondria, get better at burning fat, improve how you handle glucose. Exercise increases circulating MOTS-c levels by up to 12-fold. The peptide mimics that signal directly.
Where SS-31 protects the mitochondria you have, MOTS-c tells cells to build more capacity. It triggers the same cellular response endurance training does (AMPK activation²), helping cells build new mitochondria and shift toward more flexible fuel use. This is why MOTS-c fits training plateaus, GLP-1 fatigue, post-viral drag, and metabolic-flexibility work.
Native MOTS-c human outcome data is still developing. The strongest current anchors are the original Cell Metabolism discovery work, human physiology showing the peptide rises with exercise, and adjacent human data from CB4211, an engineered MOTS-c analog. Native MOTS-c should not be treated as the same compound as CB4211, but the analog supports the pathway.
See MOTS-c guide for more.
Component 3: NAD+ — Cellular Fuel
NAD+ is the redox currency cells spend to make energy, repair damage, regulate inflammation, and maintain circadian timing. Levels decline with age and faster under chronic stress, inflammation, caloric deficit, or post-viral load. When the pool is low, the same mitochondrial signal can land poorly because the cell lacks the currency to act on it.
Restoring NAD+ does not create energy out of nothing. It removes a bottleneck: cells can turn fuel into ATP more efficiently, fund repair work, and tolerate training or deficit pressure with less crash.
Oral precursors like NR and NMN are legitimate tools for daily pool support. Injectable NAD+ is different: it is mostly broken down outside cells into usable precursors, while also creating a stronger pulsed exposure. For at-home peptide users, IM is the preferred route for active rebuilds; SubQ can work at lower or split doses if irritation is managed.
See NAD+ Guide for a deep dive.
MOTS-c and SS-31: How They Work Together
MOTS-c and SS-31 both target mitochondria, but they do different jobs. MOTS-c is the adaptation signal. SS-31 is the structural support.
Comparison at a Glance
| Feature | MOTS-c | SS-31 (Elamipretide) |
|---|---|---|
| Origin | Natural (Mitochondrial DNA) | Synthetic |
| Main Target | AMPK Pathway / Nucleus | Cardiolipin / Inner Membrane |
| Best For | Metabolism, Fat Loss, Endurance | Recovery, Organ Health, Repair |
| Plain role | Expansion signal | Membrane protection |
Why Combine MOTS-c and SS-31?
In clinical protocols, these two are considered complementary. SS-31 is used to stabilize existing mitochondria that are struggling, reducing electron leak and oxidative stress. Once the structure is steadier, MOTS-c is used to signal for more capacity and better fuel flexibility.
Together, they cover two different bottlenecks: SS-31 protects the machinery, while MOTS-c tells the system to adapt. NAD+ is added because both processes spend redox currency.
The inflection point: when ATP production exceeds the cell's maintenance cost, it stops triaging and starts investing. Collagen renews. Nerves fire cleanly. Hormones regain sensitivity. You feel it as a shift from "managing decline" to "actually recovering."
Protocol: 12-Week Mito Stack Cycle
| Phase | SS-31 | MOTS-c | NAD+ | Support |
|---|---|---|---|---|
| Weeks 1–2 (loading) | 5–10 mg daily × 5–7 days, then 3×/week | n/a | 100–250 mg IM 2–3×/week | Electrolytes, zone-2 cardio |
| Weeks 3–6 | 5–10 mg 3×/week | 5–10 mg 2×/week | 100–250 mg IM 2–3×/week | Resistance training, protein ≥1.6 g/kg |
| Weeks 7–12 | 5–10 mg 2–3×/week | 5–10 mg 2×/week | 100–150 mg IM 1–3×/week | Sleep 7–9 hours, glycine + collagen |
Cycling: 12 weeks on, 4 weeks off. Repeat twice yearly or maintain lighter cadence (SS-31 weekly, MOTS-c pulses, NAD+ 50–150 mg weekly or 2×/week).
Route note: NAD+ is best handled IM for active rebuilds. SubQ is acceptable, but stay lower and split larger doses because it can sting, welt, or irritate. SS-31 and MOTS-c are both injection-site-reactive for many users; bacteriostatic saline (BAC water with 0.9% sodium chloride) is preferred over plain bacteriostatic water when local reactions dominate. Do not add salt manually to a vial.
Need help preparing your peptides? See the Reconstitution Guide for step-by-step instructions.
Timeline of Effects
| Timeframe | Cellular changes | What you notice |
|---|---|---|
| Weeks 1–2 | SS-31 tightens ETC, ROS drops | Warm steady energy, less soreness |
| Weeks 3–4 | MOTS-c activates AMPK/PGC-1α | Cardio feels easier, cravings decrease |
| Weeks 5–8 | NAD+ + sirtuins repair DNA/membranes | Better sleep, clearer skin, mental sharpness |
| Weeks 9–12 | Mitochondrial density peaks | Resilience under stress, faster recovery |
Applications
GLP-1 Fatigue: The Mitochondrial Bottleneck
Fatigue is one of the most common complaints among people on GLP-1 medications. Semaglutide fatigue, tirzepatide fatigue, Ozempic fatigue, Mounjaro fatigue — different drug names, same broad pattern. Weight loss works, but energy can crash, especially during titration or after months of sustained deficit.
Why it happens: GLP-1 agonists can lower intake quickly and shift more work toward fat oxidation. Burning fat requires more mitochondrial throughput than simply running on incoming carbohydrate. If the user is under-eating protein, low on electrolytes, sleeping poorly, pushing titration too fast, or already carrying inflammation or thyroid drag, the bottleneck often lands in energy production.
Why the Mito Stack helps: The stack addresses all three failure points:
- SS-31 repairs the membrane structure so electrons flow cleanly (less waste, more output)
- MOTS-c signals cells to build more mitochondria and improve fuel selection (more capacity)
- NAD+ provides the redox currency both processes require (fuel for the machinery)
The goal is simple: help mitochondria execute the fuel shift GLP-1s are creating. That does not replace food, protein, sleep, thyroid assessment, or slower titration. It supports the layer underneath them.
Practical integration: Many users start with NAD+ support first, especially during active titration or a hard caloric deficit. MOTS-c fits when training tolerance, post-exertional fatigue, or metabolic flexibility is the issue. SS-31 is the escalation layer when recovery from exertion remains slow or the fatigue pattern looks more structural than simply under-fueled.
For a complete breakdown of why each GLP-1 compound causes different types of fatigue — and the full intervention hierarchy from protein to mitochondrial support — see Why GLP-1 Medications Make You Tired. For retatrutide-specific NAD+ implementation, see the Retatrutide + NAD+ Protocol.
Injury recovery
The Mito-Stack provides the ATP foundation that tissue repair requires. In injury protocols, NAD+ can start early as the energy layer; SS-31 and MOTS-c become more relevant when fatigue, post-exertional drag, or mitochondrial recovery remains the limiter after vascular repair is underway. See our injury recovery protocol for more detail.
Longevity and anti-aging
By sustaining sirtuin activity, supporting DNA repair, and maintaining mitochondrial density, the Mito-Stack addresses the metabolic decline that underlies aging.
Side Effects and Safety
SS-31: FDA approved narrowly for Barth syndrome. Injection-site irritation, bruising, and induration are the main practical issues, especially at higher concentration or larger volume.
MOTS-c: Injection-site reactions are common. Fatigue or a glucose-dip feeling can occur if dosing is too fasted, calories are too low, or the user is methylation-sensitive.
NAD+: Slow injection rate to avoid flushing, nausea, dizziness, or chest-pressure sensations. IM is preferred for active rebuilds; SubQ should be split smaller if used.
Contraindications and cautions: Active malignancy, pregnancy or breastfeeding, acute infection or uncontrolled inflammation, severe renal impairment for SS-31, and chemotherapy regimens that depend on NAD+ depletion. Use medical oversight with heart failure, significant arrhythmia history, recent cardiac events, or uncontrolled hypertension. MTHFR carriers should start MOTS-c lower and pair with methyl-donor support.
Monitoring: Consider baseline and month-2 checks for CMP, lipids, and hs-CRP.
FAQ
Can I run the Mito Stack without NAD+ injections?
You need some form of NAD+ support for the full stack logic, but it does not have to be injectable for every user. IM NAD+ is the preferred active-rebuild route. Oral NR or NMN can work as a steadier maintenance layer or for users who do not tolerate injections.
How does The Mito Stack differ from NAD+ therapy alone?
NAD+ supports the redox pool, but it does not protect damaged mitochondrial membranes or send the adaptation signal to build more capacity. The full Mito Stack addresses structure, signaling, and substrate instead of leaning on substrate alone.
Is the Mito Stack anabolic?
Not directly muscle-building, but by improving ATP production and reducing inflammation, it makes training and any growth-hormone protocol more effective.
What is the best MOTS-c and SS-31 stack dosage?
Most protocols use MOTS-c 5–10 mg SubQ 2–3 times weekly and SS-31 5–10 mg SubQ, often loaded daily for 5–7 days before dropping to 2–3 times weekly. NAD+ commonly runs 100–250 mg IM 2–3 times weekly during active rebuilds, then lower for maintenance.
Can I take MOTS-c and SS-31 together on the same day?
Yes, but separate them by 4-6 hours or use alternating days. SS-31 stabilizes mitochondrial membrane structure (a conservation signal), while MOTS-c drives AMPK-mediated biogenesis (an expansion signal). Administering both simultaneously sends opposing instructions to the same organelle. Morning SS-31 with afternoon MOTS-c — or alternating days — lets each signal resolve before the next arrives.
Related Topics
- NAD+ Guide — Complete NAD+ overview
- BPC-157 + TB-500 for Injury Recovery — Vascular restoration
- Retatrutide + NAD+ Protocol — GLP-1 with metabolic support
- SS-31 Guide — Elamipretide — Cardiolipin stabilizer at the core of the stack
- Peptide Stacking Guide — How the Mito Stack fits into the 5-axis stacking framework
- BPC-157 Guide — Vascular repair often needed before the Mito Stack is effective
- TB-500 Guide — Cellular mobility layer often preceding the Mito Stack
- Semaglutide Guide — GLP-1 agonist — The Mito Stack addresses its mitochondrial costs
- Tirzepatide Guide — Dual-agonist — The Mito Stack supports during therapy
- Circadian Reset Protocol — How NAD+/MOTS-c support the circadian clock through the SIRT1-CLOCK/BMAL1 axis
References
SS-31 (Elamipretide)
¹ Szeto HH. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. Br J Pharmacol. 2014;171(8):2029-2050. doi:10.1111/bph.12461
² Phase 2 trials in Barth syndrome and cardiomyopathies demonstrate improved ATP kinetics and functional endpoints
MOTS-c
³ Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-454. doi:10.1016/j.cmet.2015.02.009
⁴ Kim KH, Son JM, Benayoun BA, Lee C. The mitochondrial-encoded peptide MOTS-c translocates to the nucleus to regulate nuclear gene expression. Cell Metab. 2018;28(3):516-524. doi:10.1016/j.cmet.2018.06.008
NAD+
⁵ Rajman L, Chwalek K, Sinclair DA. Therapeutic potential of NAD-boosting molecules: the in vivo evidence. Cell Metab. 2018;27(3):529-547. doi:10.1016/j.cmet.2018.02.011
- Multiple RCTs with NMN/NR precursors demonstrate tissue NAD+ elevation and functional improvements
Medical Disclaimer
The content in this protocol guide is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before beginning any new protocol, supplement, or medication.